文章：

晚期结直肠癌的治疗选择：近期随机研究的启示

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

原文发布日期：26 December 2023

DOI: 10.3390/cancers16010126

类型: Article

开放获取: 是

英文摘要：

Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).

摘要翻译： 

在过去20年中，转移性结直肠癌（mCRC）的全身治疗取得了显著进展。以5FU、奥沙利铂和伊立替康为基础的一线及二线联合方案，无论是否联合抗血管生成和/或抗EGFR抗体，均在世纪之交后不久获批应用。此后近十年间未有重大突破，直至瑞戈非尼获批，以及紧随其后的曲氟尿苷/替匹嘧啶问世。通过对肿瘤分子特征的深入解析，我们对肿瘤生物学的理解不断加深，从而催生了更多治疗选择。本文综述了mCRC后线治疗的最新临床数据，重点聚焦于现有随机试验。我们为未筛选患者群体提供了治疗建议，并针对特定肿瘤特征患者（如BRAF突变、KRAS G12C突变、HER2扩增、错配修复缺陷或NTRK基因融合）推荐了专属治疗方案。

原文链接：

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies